Search
Bethanechol
go.drugbank.com/drugs/DB01019ApprovedAn advantage of bethanechol is that in contrast to acetylcholine, bethanechol is not degraded by cholinesterase allowing its effects to be longer-lasting.[L32539] … [A232905,L32539] As a cholinergic agent, bethanechol is similar in structure and pharmacological function to acetylcholine and is used in specific cases when stimulation of the parasympathetic nervous
Metaraminol
go.drugbank.com/drugs/DB00610ApprovedIt has been used primarily as a vasoconstrictor in the treatment of hypotension. … An adrenergic agonist that acts predominantly at alpha adrenergic receptors and also stimulates the release of norepinephrine.
Macimorelin
go.drugbank.com/drugs/DB13074ApprovedGrowth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications. … While there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection
Venlafaxine
go.drugbank.com/drugs/DB00285ApprovedInvestigational[L43030] The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997. … for the management of neuropathic pain (although there is only minimal evidence of efficacy for this condition).
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: VENLAVITAE® 75 MG CÁPSULAS DURAS DE LIBERACIÓN PROLONGADAIslatravir
go.drugbank.com/drugs/DB15653ApprovedInvestigational[A275492] On April 21, 2026, the FDA approved the first fixed-dose combination containing islatravir (0.25 mg) and the NNRTI doravirine (100 mg), marketed as IDVYNSO, as a complete once-daily regimen for … Islatravir is a first-in-class, highly potent nucleoside reverse transcriptase translocation inhibitor (NRTTI) used in combination therapy for the treatment of HIV-1 infection.
Erenumab
go.drugbank.com/drugs/DB14039ApprovedInvestigationalErenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines … Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specifically developed to prevent migraine by blocking the
Florquinitau (18F)
go.drugbank.com/drugs/DB19215Approved[L64052] It binds to aggregated tau protein, which in Alzheimer's disease forms the neurofibrillary tangles (NFTs) that are one of the two components required for a neuropathological diagnosis of the disease … [L64052] After intravenous injection, florquinitau F 18 crosses the blood-brain barrier and accumulates in brain regions containing tau NFTs, allowing their distribution to be visualized and interpreted
Edrophonium
go.drugbank.com/drugs/DB01010ApprovedA rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.
Vedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigationalto its more favorable safety profile compared to its predecessor natalizumab, the first integrin receptor antagonist approved by the FDA. … [L48216] α4β7 integrin facilitates the interaction between lymphocytes and gut endothelial cells through the α4β7 integrin-MAdCAM1 interaction, leading to the mobilization of lymphocytes and thus contributing
Prednicarbate
go.drugbank.com/drugs/DB01130ApprovedThe anti-inflammation action of corticosteroids is associated with the inhibition of the interleukin 1-alpha cytokine within keratinocytes. … It has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy.
International brands: Dermatop E EmollientProducts: PREDNICARBGALEN 2.5MG/G FE